Complexes formed by mutant p53 and their roles in breast cancer
| Autor: | Daria Sicari, Licio Collavin, Arianna Bellazzo, Giannino Del Sal, Elena Valentino |
|---|---|
| Přispěvatelé: | Bellazzo, Arianna, Sicari, Daria, Valentino, Elena, Del Sal, Giannino, Collavin, Licio |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
mutant p53 gain of function
medicine.medical_treatment cancer-cell homeostasis protein–protein interactions targeted therapy Mutant Review Biology Phenotype Targeted therapy protein–protein interaction Oncology Tumor progression Gene expression Cancer cell Cancer research medicine cancer-cell homeostasi Gene Transcription factor |
| Zdroj: | Breast Cancer : Targets and Therapy |
| Popis: | Breast cancer is the most frequently diagnosed malignancy in women, and mutations in the tumor suppressor p53 are commonly detected in the most aggressive subtypes. The majority of TP53 gene alterations are missense substitutions, leading to expression of mutant forms of the p53 protein that are frequently detected at high levels in cancer cells. P53 mutants not only lose the physiological tumor-suppressive activity of the wild-type p53 protein but also acquire novel powerful oncogenic functions, referred to as gain of function, that may actively confer a selective advantage during tumor progression. Some of the best-characterized oncogenic activities of mutant p53 are mediated by its ability to form aberrant protein complexes with other transcription factors or proteins not directly related to gene transcription. The set of cellular proteins available to interact with mutant p53 is dependent on cell type and extensively affected by environmental signals, so the prognostic impact of p53 mutation is complex. Specific functional interactions of mutant p53 can profoundly impact homeostasis of breast cancer cells, reprogramming gene expression in response to specific extracellular inputs or cell-intrinsic conditions. The list of protein complexes involving mutant p53 in breast cancer is continuously growing, as is the number of oncogenic phenotypes in which they could be involved. In consideration of the functional impact of such complexes, key interactions of mutant p53 may be exploited as potential targets for development of therapies aimed at defusing the oncogenic potential of p53 mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|